Lipid droplets in the liver are coated with the perilipin family of proteins, notably Adipocyte Differentiation-Related Protein (ADRP) and Tail Interacting Protein of 47 kD (TIP47). ADRP is increased in hepatic steatosis and associated with hyperlipidemia, insulin resistance and glucose intolerance. We have shown that reducing ADRP in the liver via antisense oligonucleotide (ASO) treatment attenuates steatosis and improves insulin sensitivity and glucose tolerance. We hypothesized that TIP47 has similar effects on hepatic lipid and glucose metabolism. We found that TIP47 mRNA and protein levels were increased in response to a high-fat diet (HFD) in C57BL/6J mice. TIP47 ASO treatment decreased liver TIP47 mRNA and protein levels without altering ADRP levels. Low dose TIP47 ASO (15 mg/kg) and high dose TIP47 ASO (50 mg/kg) decreased triglyceride content in the liver by 35% and 52%, respectively. Liver histology showed a drastic reduction in hepatic steatosis following TIP47 ASO treatment. The high dose of TIP47 ASO significantly blunted hepatic triglyceride secretion, improved glucose tolerance, and increased insulin sensitivity in liver, adipose tissue and muscle. These findings show that TIP47 affects hepatic lipid and glucose metabolism, and may be a target for the treatment of nonalcoholic fatty liver and related metabolic disorders.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions in the United States and worldwide, and is closely associated with obesity and type 2 diabetes (1, 4, 20, 31) . As in humans, mice fed a high fat diet develop fatty liver characterized by excessive accumulation of lipid droplets, consisting of a neutral lipid core, mainly triglycerides, surrounded by a phospholipid monolayer (2, 20, 30) . The surface of lipid droplets is coated by a perilipin family of proteins, metabolic enzymes and vesicle trafficking proteins (2) (3) (4) (5) . Adipose differentiation related protein (ADRP) (also named Perilipin 2) and Tail Interacting Protein (TIP)47 (also named Perilipin 3) are the major lipid droplet proteins in hepatocytes (2) (3) (4) (5) 17) .
Ablation of Adfp gene decreased hepatic steatosis, increased very low density lipoprotein (VLDL) secretion, and improved insulin sensitivity in ob/ob mice (7, 8) . We have shown that an antisense oligonucleotide (ASO) against ADRP reduced steatosis and VLDL secretion, and enhanced hepatic insulin sensitivity in ob/ob and diet-induced obese (DIO) mice (16, 30) .
As with ADRP, TIP47 is widely expressed in hepatocytes, enterocytes, macrophages and other tissues, and is increased in response to lipid loading (2, 6, 12, 13, 18, 26) . In Adfp null adipocytes, TIP47 compensates for the loss of ADRP and maintains triglyceride accumulation in lipid droplets (26) . In Hela cells, TIP47 is recruited to lipid droplets and displays apolipoproteinlike properties by inducing the formation of synthetic lipid droplet-like particles (6) . Inhibition of TIP47 in HeLa cells decreases triglyceride incorporation and maturation of lipid droplets (6) .
However, the specific in vivo functions of TIP47 are unknown. The aim of this study was to determine whether TIP47 ASO treatment would reduce hepatic steatosis and circulating lipid levels, and improve glucose homeostasis.
MATERIALS AND METHODS

Mouse model of hepatic steatosis
Experiments were performed according to protocols reviewed and approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania School of Medicine. Eight-week old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were housed (n = 5 per cage) under a 12:12-h light-dark cycle (light on at 0700) and an ambient temperature of 22°C and allowed free access to water and food. We first determined whether 4 weeks of high fat diet (HFD) would increase TIP47 and ADRP expression in liver. (15, 24, 27, 28, 30) . Body composition was measured with nuclear magnetic resonance (Echo MRI, Houston, TX) (16, 24, 30) . Very low density lipoprotein (VLDL) secretion was measured after Poloxamer treatment as described below (16, 24, 30) . Mice were euthanized 3 days later and livers were harvested for measurement of TIP47, ADRP and triglyceride levels.
TIP47 antisense oligonucleotide (ASO) treatment
Eight-week old male C57BL/6J mice were fed HFD ad libitum, received saline vehicle, 15 mg/kg TIP47 ASO (low dose), 50 mg/kg TIP47 ASO (high dose) or control ASO via intraperitoneal injection (IP) twice a week for 4 weeks, and continued on HFD throughout the treatment. Chimeric second-generation ASOs were synthesized by ISIS Pharmaceuticals (Carlsbad, CA) and formulated in phosphate-buffered saline (10, 16, 23, 30, 33) . TIP47 ASO, ISIS 409003 (5′CACAGTGTTGTCTAGGGCCT3′), is a 20-mer phosphorothioate oligonucleotide complementary to the mRNA for mouse TIP47, and has 2′-O-methoxyethylmodified ribonucleosides (2′-MOE) at the 3′-and 5′-ends with 2′-deoxynucleosides in between.
A control oligonucleotide, ISIS 141923 (5′CCTTCCCTGAAGGTTCCTCC-3′), contains similar chemical modifications, with no complementarity to known genes including lipid droplet proteins. The cytosines in all of these molecules are methylated. The efficacy of TIP47 ASO was first tested in primary mouse hepatocytes as described for other ASOs (10, 32) . Food intake and body weight were measured twice a week.
Lipid and glucose testing
To determine the rate of VLDL secretion from the liver, mice were fasted for 4 hours in the morning (0800-1200), 3 days after ASO or saline treatment. A detergent, Polaxamer-407 (1g/kg IP), was administered to inhibit lipases, and tail blood was obtained at time 0, and 1, 2 and 4 hours later (16, 24, 30) . Triglyceride levels were measured in serum with an enzyme assay as previously described (16, 24, 30) .
To determine glucose tolerance, mice were fasted overnight, glucose solution (2g/kg) was injected IP, and tail blood glucose was measured at time 0 (before glucose injection) and 15, 30, 60, 90, and 120 minutes later with a glucometer (One Touch Ultra, Johnson & Johnson) (16, 24, 30) . To determine tissue-specific insulin sensitivity, a hyperinsulinemic-euglycemic clamp was performed as described (30) . An indwelling catheter was inserted in the right internal jugular vein and extended to the right atrium. After recovery of the pre-surgery weight in 4 days, the mice were fasted for 6 hours, and administered a bolus injection of 5 μCi of [3- and soleus muscle were excised, frozen immediately in liquid nitrogen, and stored at -80°C for subsequent analysis of glucose uptake (30) .
Tissue chemistry
Three days after the last TIP47 ASO, control ASO or saline treatment, mice were euthanized at 12 noon-1 PM, blood was obtained via cardiac puncture, and liver samples were rapidly dissected, frozen in liquid nitrogen and stored at −80°C. Serum insulin concentration was measured with an ELISA (Crystal Chem, Evanston, IL). Total and high molecular weight adiponectin concentrations were measured with an ELISA (Alpco, Salem, NH). Lipids were extracted from livers for triglyceride measurement (16, 24, 28, 30) . RNA was extracted from livers, muscle and WAT of TIP47 using Trizol reagent (Invitrogen, Carlsbad, CA), and expression of mRNA levels of TIP47, ADRP, and enzymes involved in lipogenesis and lipolysis were measured using real-time polymerase chain reaction (PCR) (ABI Prism; Applied Biosystems, Foster City, CA) (16, 24, 28, 30) . The level of mRNA expression was normalized to phosphoriboprotein (36B4).
TIP47 and ADRP protein levels in liver were determined by immunoblotting (16, 30) . Liver samples were homogenized in lysis buffer containing 1% NP-40; 0.5% Triton,10% 
RESULTS
HFD increases hepatic steatosis, TIP47 and ADRP expression and triglyceride secretion.
Body weight and total fat content were increased slightly but not significantly in C57BL/6J mice fed a HFD for 4 weeks (Fig. 1A, B) . On the other hand, there was a 3-fold increase in liver triglyceride content (Fig. 1C) , and triglyceride secretion (Fig. 1D ) was significantly increased after 4 weeks on HFD compared to normal chow diet. The relative mRNA and protein levels of TIP47 and ADRP were significantly increased in HFD livers compared to normal chow diet (Fig. 1E-G) .
TIP47 ASO reduces hepatic TIP47 expression without compensatory increase in ADRP.
As compared with saline and control ASO groups, TIP47 ASO treatment reduced hepatic TIP47 mRNA by approximately 70% without changing ADRP mRNA level ( Fig. 2A-B) .
Immunoblotting of liver lysates showed that treatment with TIP47 ASO decreased the TIP47 protein level without changing ADRP liver protein level (Fig. 2C ). This was confirmed by immunohistochemistry of liver sections which showed a reduction in TIP47 immunostaining following TIP47 ASO treatment compared to saline or control ASO (Fig. 3A-C) . TIP47 ASO treatment decreased hepatic steatosis as evidenced by a drastic reduction in Oil Red O staining in liver sections of TIP47 ASO-treated mice compared to saline or control ASO (Fig. 3D-F) .
TIP47 ASO did not significantly change the relative expression of TIP47 and ADRP mRNA in white adipose tissue ( Figure 4A, B) . Furthermore, there was no apparent change in ADRP immunostaining in the liver following TIP47 ASO treatment (Fig. 4C) .
TIP47 ASO reduces hepatic triglyceride content and triglyceride secretion.
The low and high doses of TIP47 ASO significantly decreased hepatic triglyceride content by 35% and 52%, respectively (Fig. 5A) . Hepatic triglyceride secretion was measured to determine if the reduction in hepatic triglyceride content following TIP7 ASO treatment was due to an increase in triglyceride secretion. The low dose TIP47 ASO had no effect on hepatic triglyceride secretion, while the high dose TIP47ASO significantly reduced hepatic triglyceride secretion (Fig. 5B) . Food intake and body weight were not affected by TIP47 ASO treatment (Table 1) . The low dose TIP47 ASO did not change the body composition, however, the high dose TIP47 ASO decreased total body fat compared to the control ASO (Table 1) .
We examined the effects of TIP47 ASO on enzymes involved in lipid metabolism ( Fig.   6A-E) . TIP47 ASO treatment significantly reduced the mRNA expression of Dgat2 and Gpat, suggesting a major effect on lipogenesis.
Reduction of TIP47 improves glucose homeostasis.
Glucose levels were similar in the four groups of mice. Insulin levels were significantly lower, and total and high molecular weight (HMW) adiponectin levels were higher in the TIP47 ASO group (Table 1) . We performed a glucose tolerance test to determine whether the reduction in hepatic steatosis in TIP47 ASO-treated mice affected glucose homeostasis. The high dose TIP47 ASO significantly improved glucose tolerance (Fig. 5C ). There was a trend toward improved glucose tolerance in the low dose TIP47 ASO group, but this did not reach statistical significance, suggesting a dose dependent effect of TIP47 ASO treatment (Fig. 5C ).
In order to evaluate the effects of TIP47 ASO on insulin sensitivity in the liver and other organs, we assessed glucose kinetics under basal (fasting) and hyperinsulinemic-euglycemic clamp (30) . The basal hepatic glucose production after 6 hours of fasting was similar among all groups (Fig. 7A) . Under hyperinsulinemc clamp, the high dose TIP47 ASO significantly increased the glucose infusion rate (GIR) needed to reach the target blood glucose concentration of ~140 mg/dL (Fig. 7B) , decreased hepatic glucose production (HGP) (Fig. 7C) , and increased the glucose disposal rate (Rd) (Fig. 7D) . The high dose TIP47 ASO increased glucose uptake in adipose tissue and skeletal muscle (Fig. 7E, F) . Together, these results demonstrated that TIP47 ASO treatment improved both hepatic and peripheral insulin sensitivity.
DISCUSSION
Mammals normally store most of their energy in the form of triglycerides in perilipincoated lipid droplets in adipocytes (2, 12) . However, obesity results in ectopic accumulation of lipid droplets in non-adipose tissues, e.g. liver, skeletal and cardiac muscle and pancreatic islets, and this has been linked to insulin resistance and organ dysfunction (29) . Fatty liver is characterized by excessive accumulation of triglyceride-rich lipid droplets coated with ADRP, TIP47, OXPAT and other proteins (12, 16, 19, 22, 25, 30 ). In the current study, we found that HFD increased triglyceride, ADRP and TIP47 levels in livers of C57BL/6J mice. Previous studies showed that fatty acids increased ADRP and triglyceride levels in hepatocytes (11, 13, 22) . Conversely, a reduction in ADRP levels decreased triglyceride accumulation in hepatocytes (11, 13, 22) . Ablation of the Adfp gene in mice reduced hepatic lipid droplets and triglyceride content in lean, diet-induced obese (DIO) and ob/ob mice, and increased VLDL secretion and insulin sensitivity in ob/ob mice (7, 8) . We have also shown that reducing ADRP via ASO treatment attenuated hepatic steatosis and improved insulin sensitivity in DIO and ob/ob mice (16, 30) . However, unlike genetic ADRP deficiency, ASO treatment reduced VLDL secretion in obese mice (16, 30) .
We predicted that TIP47 would exert similar actions on hepatic lipids and glucose homeostasis as ADRP. We successfully reduced TIP47 mRNA and protein levels in HFD liver using ASO treatment. The low (15 mg/kg) and high (50 mg/kg) doses of TIP47 ASO both decreased hepatic TIP47 mRNA and protein without changing ADRP levels. TIP47 ASO did not significantly change TIP47 or ADRP expression in adipose tissue. TIP47 ASO decreased hepatic triglycerides in a dose-dependent manner. Similar to our previous results in ADRP ASO-treated mice, TIP47 ASO suppressed Dgat2 and Gpat expression in HFD liver, suggesting inhibition of lipogenesis (9, 16, 30) . The high dose of TIP47 ASO suppressed hepatic triglyceride secretion, and improved glucose tolerance, and insulin sensitivity in liver, adipose tissue and muscle.
The ability of TIP47 ASO treatment to regulate hepatic lipids is consistent with studies in other tissues. In Hela cells, TIP47 is recruited to lipid droplets and is actively involved in organizing and expanding lipid droplets (6) . Conversely, siRNA knockdown of TIP47 prevents lipid droplet maturation and triglyceride accumulation in Hela cells (6) . In human macrophages, TIP47 is localized in the plasma membrane and aggregates into clusters surrounding lipid droplets in response to oleic acid loading (5). TIP47 maintains triglyceride levels when macrophages are depleted of ADRP; however, siRNA knockdown of TIP47 in ADRP-deficient macrophages reduces triglyceride accumulation (6) . These results demonstrate that TIP47 can compensate for ADRP deficiency during conversion of macrophages into foam cells (6) . A similar relationship exists between ADRP and TIP47 in murine adipocytes (26) . Adfp null adipocytes form lipid droplets to the same extent as wild type adipocytes, but siRNA knockdown of TIP47 reduces triglyceride accumulation and lipid droplets in ADRP deficient adipocytes (26) . In our study, TIP47 ASO treatment did not change ADRP expression in liver and adipose tissue. In primary rat hepatocytes, TIP47 is increased rapidly by fatty acids followed by a slow decline, while ADRP is increased steadily during fatty acid exposure (13) . In small intestine enterocytes, TIP47 levels are increased rapidly in enterocytes in response to acute ingestion of HFD, while ADRP levels are increased in response to chronic HFD (18) . It is possible TIP47 and ADRP have different roles in the early response to excess lipids and long term lipid storage.
Hepatic steatosis is commonly associated with insulin resistance, impaired glucose tolerance and type 2 diabetes (1, 4, 20) . Insulin resistance in hepatic steatosis is mediated by lipid metabolites, e.g. ceramides, long chain fatty acyl CoAs and diacylglycerol (5, 14, 20) . Diacyl glycerol activates protein kinase C (PKC)ε in the liver resulting in inhibition of insulin signaling (20, 21) . Reduction of activities of enzymes involved in hepatic lipid synthesis and pathogenesis of steatosis improves insulin sensitivity (9, 21, 23) . We have previously reported that ADRP ASO treatment improved glucose tolerance and insulin sensitivity in diet-induced obese and ob/ob mice (16, 30 ). In our current study, TIP47 ASO improved glucose tolerance in a dose dependent manner. Moreover, the high dose of TIP47 ASO significantly enhanced insulin sensitivity in the liver, adipose tissue and skeletal muscle. Total and HMW adiponectin levels were higher in TIP47 ASO treated mice, suggesting a potential role in the enhancement of insulin sensitivity (32).
Our results demonstrate that TIP47 is connected to hepatic lipid and glucose metabolism in vivo independently of ADRP. We propose that TIP47 is stimulated by HFD, coats the surface of lipid droplets, prevents hydrolysis of triglycerides, and promotes hepatic steatosis (22) .
Further research is needed to determine how TIP47 and other lipid droplet proteins in the liver are temporally and spatially regulated by dietary lipids. It is also crucial to determine how TIP47 interacts with other lipid droplet proteins to regulate lipid pools and metabolites implicated in insulin signaling in liver, adipose tissue and muscle.
PERSPECTIVES AND SIGNIFICANCE
Lipid droplets are intracellular organelles that store neutral lipids in various organs.
Studies over the past two decades have shown that lipid droplets regulate the storage and hydrolysis of neutral lipids, including triacylglycerol and cholesterol esters. Alterations in lipid droplet metabolism influence the risk of developing NAFLD, diabetes and other metabolic diseases. Lipid droplets in liver are coated with ADRP (Plin2), TIP47 (Plin3) and other members of the perilipin family. In the current study we demonstrate that TIP47 is increased in fatty liver, and that treatment with TIP47 ASO reduces hepatic steatosis, improves glucose tolerance, and enhances hepatic and peripheral insulin sensitivity. We did not observe a compensatory increase in ADRP in livers of TIP47 ASO treated mice, suggesting that TIP47 regulates lipids and glucose independently of ADRP. Further understanding of the molecular interactions between TIP47 and pathways involved in lipid metabolism will provide new insights to the pathogenesis of NAFLD and metabolic syndrome, and potentially lead to novel therapies for lipid disorders and diabetes. 
